We are live on ! Find out more
ASMB icon

Assembly Biosciences
ASMB

98 hedge funds and large institutions have $204M invested in Assembly Biosciences in 2019 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 32 increasing their positions, 37 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

4,252% more call options, than puts

Call options by funds: $5.48M | Put options by funds: $126K

0.16% less ownership

Funds ownership: 6.88% → 6.72% (-0.16%)

8% less funds holding

Funds holding: 106 → 98 (-8)

14% less repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 37

29% less capital invested

Capital invested by funds: $286M → $204M (-$82.3M)

42% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 19

Holders
98
Holders Change
-8
Holders Change %
-7.55%
% of All Funds
2.15%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
32
Reduced
37
Closed
19
Calls
$5.48M
Puts
$126K
Net Calls
+$5.36M
Net Calls Change
-$2.3M

Top Buyers

Rank Fund Capital Flow
1
RSCM
Rock Springs Capital Management
Maryland
+$9.33M
2
AC
Armistice Capital
New York
+$5.9M
3
CCPM
Cooper Creek Partners Management
New York
+$3M
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$2.36M
5
SFM
Sphera Funds Management
Israel
+$1.51M

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$7.06M
2
Wellington Management Group
Wellington Management Group
Massachusetts
-$3.54M
3
Jennison Associates
Jennison Associates
New York
-$2.71M
4
PM
Prosight Management
Texas
-$2.7M
5
Millennium Management
Millennium Management
New York
-$2.53M
Name Holding Trade Value Shares
Change 		Change in
Stake
Deutsche Bank
26
Deutsche Bank
Germany
$1.42M -$811K -5,363 -31%
ACP
27
Acuta Capital Partners
California
$1.29M -$334K -2,209 -17%
CM
28
Caption Management
Oklahoma
$1.23M -$359K -2,375 -19%
Renaissance Technologies
29
Renaissance Technologies
New York
$1.23M -$105K -692 -6%
Charles Schwab
30
Charles Schwab
California
$1.23M +$908 +6 +0.1%
SFM
31
Sphera Funds Management
Israel
$1.18M +$1.51M +10,000 New
Susquehanna International Group
32
Susquehanna International Group
Pennsylvania
$1.11M -$769K -5,082 -35%
Bank of New York Mellon
33
Bank of New York Mellon
New York
$987K -$45.5K -301 -3%
BFM
34
Boothbay Fund Management
New York
$985K +$72.5K +479 +6%
EC
35
EcoR1 Capital
California
$950K +$1.22M +8,050 New
Two Sigma Investments
36
Two Sigma Investments
New York
$783K -$896K -5,920 -47%
Two Sigma Advisers
37
Two Sigma Advisers
New York
$775K +$275K +1,817 +38%
Barclays
38
Barclays
United Kingdom
$732K -$347K -2,293 -27%
Goldman Sachs
39
Goldman Sachs
New York
$670K +$423K +2,796 +97%
Squarepoint
40
Squarepoint
New York
$579K +$526K +3,480 +244%
Russell Investments Group
41
Russell Investments Group
United Kingdom
$576K +$737K +4,874 New
Assenagon Asset Management
42
Assenagon Asset Management
Luxembourg
$524K -$554K -3,661 -45%
AA
43
ALPS Advisors
Colorado
$504K -$28K -185 -4%
DCM
44
DAFNA Capital Management
California
$497K – – –
OM
45
Opaleye Management
Massachusetts
$492K +$630K +4,167 New
Marshall Wace
46
Marshall Wace
United Kingdom
$476K +$303K +2,003 +99%
Swiss National Bank
47
Swiss National Bank
Switzerland
$420K – – –
PP
48
PDT Partners
New York
$387K -$59.3K -392 -11%
VFA
49
Valeo Financial Advisors
Indiana
$355K -$2.08M -13,736 -82%
RhumbLine Advisers
50
RhumbLine Advisers
Massachusetts
$343K +$33.7K +223 +8%
1
2
3 4 5

ASMB Hedge Fund Activity: Q3 2019 in Review

98 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Assembly Biosciences (ASMB) for Q3 2019, worth a combined $204M — down 29% from $286M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of ASMB and 11 opened new positions — a net loss of 8 holders — while 37 trimmed existing stakes and 32 added.

The largest buyer was Rock Springs Capital Management, adding an estimated $9.33M. The largest seller was OrbiMed, exiting entirely with an estimated $7.06M sold.

  • 98 institutional investors held Assembly Biosciences (ASMB) as of Q3 2019, down from 106 in Q2 2019.
  • Funds reported $204M of Assembly Biosciences stock for Q3 2019, down 29% quarter-over-quarter.
  • 11 funds opened new Assembly Biosciences positions in Q3 2019 and 19 closed out, a net change of -8 holders.
  • The largest Assembly Biosciences buyer in Q3 2019 was Rock Springs Capital Management, an estimated $9.33M added.
  • The largest Assembly Biosciences seller in Q3 2019 was OrbiMed, an estimated $7.06M sold.

Based on aggregated 13F filings for Q3 2019.